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Summary A total of 458 eligible patients, from 21 centres, with microscopically confirmed SCLC were
allocated at random to three chemotherapy regimens, each given at 3-week intervals. In two regimens,
etoposide, cyclophosphamide, methotrexate and vincristine were given for a total of either three courses
(ECMV3) or six courses (ECMV6). In the third regimen, etoposide and ifosfamide were given for six courses
(EI6). Patients with limited disease also received radiotherapy to the primary site after the third course of
chemotherapy in all three groups. As reported by clinicians, 59% of the ECMV3, 67% of the ECMV6 and
63% of the E16 patients experienced moderate or severe adverse reactions to their chemotherapy. The major
symptoms of disease, cough, haemoptysis, chest pain, anorexia, and dysphagia, were palliated in 63% or more
of patients and the median duration of palliation was 63% or more of survival, the results being similar in the
three groups. Among patients with poor overall condition, physical activity and breathlessness on admission,
the proportions who improved were higher in the EI6 group but the differences were small. In all three groups,
levels of anxiety fell substantially during treatment. Levels of depression were lower and showed little change.
As assessed by patients using a daily diary card, the patterns of nausea, vomiting, activity and mood,
associated with courses of chemotherapy were very similar in the three groups. In the E16 group there was less
dysphagia and better overall condition between courses, but these advantages need to be weighed against the
inconvenience of the 24-h infusions required, compared with the 30-min infusions of the other two regimens.
As reported in the companion paper (MRC Lung Cancer Working Party, 1993a) there was no statistically
significant survival advantage to any of the three regimens, although the results do not exclude the possibility
of a minor survival advantage with the two six-course regimens. In conclusion, there was no major clinical
gain from continuing chemotherapy beyond three courses or from using the ifosfamide regimen.
Small cell lung cancer is usually highly sensitive to cytotoxic
chemotherapy and radiotherapy, although long-term survival
rates among patients treated with these modalities are low.
The aims of treatment are to control symptoms of the disease
and to prolong survival. The treatment is troublesome to the
patient, however, and may be toxic. A number of randomised
trials have therefore attempted to determine the minimum
number of courses of chemotherapy that can be given with-
out incurring therapeutic penalties (Cullen et al., 1986; Spiro
et al., 1989; MRC Lung Cancer Working Party, 1989; 1993a;
Giaccone et al., 1993). The main aims of the present ran-
domised trial were to investigate whether six courses of
etoposide, cyclophosphamide, methotrexate, and vincristine
(ECMV6), a regimen previously studied by the MRC Lung
Cancer Working Party (1989), could be reduced to three
courses (ECMV3) without compromising survival, and to
compare these regimens with six courses of etoposide and
ifosfamide (EI6). The comparisons of response, survival, and
prognostic factors, based on 458 eligible patients, have been
presented in the accompanying report (MRC Lung Cancer
Working Party, 1993a), hereinafter referred to as Paper 1.
They show that there was no statistically significant advan-
tage in duration of survival to any of the three regimens,
although the possibility of a survival advantage with the two
six-course regimens cannot be discounted (Hazard
Ratio = 1.1).
The quality as well as the duration of survival is important
for these patients and both need to be studied in randomised
treatment comparisons. Although performance status scores
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such as the Karnofsky index (Karnofsky & Burchenal, 1949)
and the WHO performance scale (World Health Organiza-
tion, 1979) are often used in randomised trials, and the main
toxic effects of treatment reported, comparisons of symptom
control and of other aspects of quality of life are rarely made
(Bergman, 1992; Fayers, 1992). Quality of life endpoints
should be included in trials ofpalliative treatment, bearing in
mind that quality of life is a multi-dimensional concept which
includes palliation of symptoms, adverse effects of treatment,
physical well-being and psycho-social factors.
The present trial is therefore important in that clinicians
reported not only on the adverse effects of treatment but also
on the patients' symptoms, overall condition, and level of
physical activity, and patients were asked to complete a diary
card (Fayers et al., 1991) on a daily basis during chemo-
therapy to provide information on symptoms, level of
physical activity, mood, and overall condition during the
period when these were likely to be changing substantially
from day to day. The diary cards thus allowed patients
themselves to assess their quality of life in the above
domains. The objectives of this paper are to report the
findings on quality of life, to discuss the associated problems
of compliance in providing quality of life data, and to com-
ment on methodological problems associated with the
analysis and interpretation of quality of life data.
Methods
Patients and trial design
The design of the trial is described in detail in Paper 1. In
summary, the patients had previously untreated, micro-
scopically confirmed small cell lung cancer of any extent.
They could have any level of performance status but had to
be expected to benefit from chemotherapy. Local ethics com-
mittee approval of the protocol and individual patient con-
sent were required. The patients were randomly allocated to
one of three treatment regimens.
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Treatment regimens
The treatment regimens are described in detail in Paper 1.
They are summarised here. Each was given on 3 consecutive
days at 3-week intervals.
ECMV3 The ECMV3 regimen comprised three courses of
chemotherapy. On day 1, etoposide was given by intravenous
infusion over 30 min, together with cyclophosphamide,
methotrexate and vincristine by intravenous injection. On
days 2 and 3, etoposide was given either intravenously or
orally. Patients with limited disease (defined in Paper 1) were
also given thoracic radiotherapy to a midline dose of 40 Gy
in 15 daily fractions over 3 weeks starting 3 weeks after the
third course of chemotherapy.
ECMV6 The ECMV6 regimen comprised six courses of the
same chemotherapy as the ECMV3 regimen. Patients with
limited disease also received thoracic radiotherapy, as above,
after the third course of chemotherapy, the fourth course
being given 3 weeks after the end of radiotherapy.
EI6 The E16 regimen comprised six courses of chemo-
therapy. Etoposide was given as above. On day 1 it was
followed by ifosfamide plus mesna by intravenous infusion
over 24 h and on day 2 by mesna by intravenous infusion
over 12 h. If the etoposide was given orally, the mesna could
be given orally. Mesna was incorporated to prevent urotox-
icity (Brock & Pohl, 1983). Patients with limited disease also
received the same thoracic radiotherapy as in the ECMV6
regimen.
Clinicians' assessment ofquality oflife
Clinicians assessed patients pretreatment, at each attendance
for treatment, then monthly to 12 months, and then every 3
months thereafter. At each assessment they asked the
patients about the occurrence and severity of the symptoms
listed in Table I, recording the answers as none, mild,
moderate, or severe. They also recorded the patients' overall
condition, level of physical activity (World Health Organiza-
tion, 1979), and degree of breathlessness according to the
categories shown in the table. At all assessments after the
pretreatment assessment, they were asked to complete their
record according to the patient's condition since the previous
assessment.
Patients' assessment using the diary card
For their first 21 weeks in the trial, the patients were asked
to complete an MRC patient diary card (Fayers et al., 1991)
every evening after their last meal, recording how they had
been feeling during the previous 24 h. They coded their
assessments as shown in Table I. The purpose of these cards
was to record the patients' own daily assessments of a few
key aspects of their quality of life when these were likely to
be changing substantially from day to day, namely, during
the period of chemotherapy and - when given - radio-
therapy. Each card covered a period of up to 5 weeks and
patients were issued with a spare card because, although
clinic attendances should have been at intervals of 3 weeks,
there could sometimes be delays. Patients were asked to bring
their current card or cards to their next clinic appointment.
Statistical methods
TableI Scales used by the clinicians and on thedailydiary card by the
patients
Clinicians' assessment Patient's assessment (diary card)
Nausea
0 None
I Mild
2 Moderate
3 Severe
Vomiting
0 None
1 Mild
2 Moderate
3 Severe
Difficulty in swallowing
0 None
1 Mild
2 Moderate
3 Severe
Activity
0 Normal without restriction
1 Strenuous activity restricted,
can do light work
2 Up and about > 50% of
waking hours, unable to work,
capable of all self-care
3 Confined to bed or chair
> 50% ofwaking hours,
limited self-care
4 Confined to bed or chair, no
self-care
Anxiety Depression
0 None 0 None
1 Mild 1 Mild
2 Moderate 2 Moderate
3 Severe 3 Severe
Overall condition
0 Excellent
1 Good
2 Fair
3 Poor
4 Very poor
Degree ofbreathlessness
0 Climbs hills or stairs without
dyspnoea
1 Walks any distance on flat
without dyspnoea
2 Walks over 100 yards without
dyspnoea
3 Dyspnoea on walking 100
yards or less
4 Dyspnoea on mild exertion,
e.g. undressing
Also recorded as none, mild,
moderate, or severe
1 Cough
2 Haemoptysis
3 Chest pain
4 Other pain - state site(s)
5 Anorexia
6 Sore mouth, tongue, lips
7 Diarrhoea
8 Cystitis
9 Numbness, paraesthesia
10 Other suspected adverse
effects of treatment - WHO
grade where available
11 Other- specify
0 None
I Mild
2 Moderate
3 Severe
0 None
1 Sick once
2 Sick 2 or 3 times
3 Sick 4 or more times
0 None
1 Mild soreness only
2 Can swallow solids with
difficulty
3 Cannot swallow solids
4 Cannot swallow liquids
0 Normal work/house-work
1 Normal work but with effort
2 Reduced activity but not
confined to home
3 Confined to home or hospital
4 Confined to bed
Mood
0 Very happy
1 Happy
2 Average
3 Miserable
4 Very miserable
0 Very well
1 Well
2 Fair
3 Poor
4 Very ill
Compliance in the completion of clinicians' reports was cal-
culated on the basis that the question on symptoms should
have been answered every time a patient was expected to
attend for treatment or follow-up. For convenience, a single
symptom (nausea) was selected for the calculation. Com-
pliance in the use of the patient diary cards was calculated as
the percentage of days in the first 21 weeks, or to death if
this was sooner, that each patient completed the card.
Palliation of a symptom was defined as disappearance of
the symptom or improvement by one or more categories at
one or more assessments. Duration of palliation is expressed
(i) as the median duration ofpalliation and (ii) as the percen-
tage of patient survival time during which there was pallia-
tion. The variation in these two statistics is expressed by the
interquartile range (Q), which is the range of the two middle
quarters of the results. Measures of the duration of palliation
were necessarily approximate because patients were being
assessed every 3 weeks during treatment and then monthly toQUALITY OF LIFE IN SCLC 1159
1 year. In the drawing up of the daily profiles from the diary
cards (see Figures) allowance was made for delays in giving
some courses of chemotherapy. Since each course of
chemotherapy is likely greatly to affect the quality of life of
the patients, the mean time between each course was cal-
culated and the profiles for each patient were realigned to
this schedule. The methodology was the same as in previous
MRC trials (Fayers et al., 1991; MRC Lung Cancer Working
Party, 1991; 1992).
The trial data were managed using the COMPACT pro-
gram (COMPACT Steering Committee, 1991).
Results
Patients in the trial
Between February 1985 and April 1989, 491 patients were
admitted to the trial from 21 centres in the United Kingdom.
Of these, 33 were ineligible (Paper 1), leaving 458 (157
ECMV3, 152 ECMV6, 149 EI6) for analysis.
The main symptoms, overall condition and level of
physical activity of the patients as assessed on admission by
the clinicians are shown in Table II. Most (84%) of the
patients had cough (moderate or severe in 38%), and 31%
had haemoptysis, 47% chest pain, 51% anorexia, and 8%
dysphagia. The overall condition, level of physical activity,
and degree of breathlessness were normal or nearly normal
(grade 0 or 1) in 62%, 63%, and 52%, respectively. The
distributions of all these variables were similar in the three
treatment groups.
Clinicians' andpatients' compliance in completingforms and
diary cards
The compliance by clinicians in providing quality of life data
at the time of clinic attendances by patients (Table III) was
high, 90% of the expected data being provided. The centre
that provided no data entered only a single patient. All other
centres provided more than 50% of data and 11 provided
90% or more. In marked contrast, only 47% of the expected
data from the patient diary cards was received, a third of the
patients providing no data at all, and only a third providing
more than 75% of the expected data. There was considerable
Table II Characteristics of the patients on admission as recorded by the clinicians
ECMV3 ECMV6 EI6 Total
Characteristic No. (%) No. (%) No. (%) No. (%)
Cough
None
Mild
Moderate
Severe
Not known
Haemoptysis
None
Mild
Moderate
Severe
Not known
Chest pain
None
Mild
Moderate
Severe
Not known
Anorexia
17
73
64
3
0
97
52
5
0
3
79
43
30
4
1
None 74
Mild 54
Moderate 24
Severe 3
Not known 2
)ysphagia
None 143
Mild 5
Moderate 3
Severe 0
Not known 6
)verall conditiona
0 15
1 75
2 55
3 8
4 1
Not known 3
,evel ofphysical activitya
0 28
1 68
2 46
3 10
4 1
Not known 4
egree ofbreathlessnessa
0 27
1 45
2 37
3 33
4 10
Not known 5
'Definitions given in Table I.
(11)
(46)
(41)
(2)
(63)
(34)
(3)
(0)
(51)
(28)
(19)
(3)
(48)
(35)
(15)
(2)
(95)
(3)
(2)
(0)
(10)
(49)
(36)
(5)
(1)
(18)
(44)
(30)
(7)
(1)
(18)
(30)
(24)
(22)
(7)
23
69
52
6
2
106
36
8
0
2
86
32
26
5
3
72
44
24
7
5
131
8
5
2
6
18
76
43
9
2
4
27
63
38
15
2
7
22
54
36
27
8
5
(15)
(46)
(35)
(4)
(71)
(24)
(5)
(0)
(58)
(21)
(17)
(3)
(49)
(30)
(16)
(5)
(90)
(5)
(3)
(1)
(12)
(51)
(29)
(6)
(1)
(19)
(43)
(26)
(10)
(1)
(15)
(37)
(24)
(18)
(50)
32
68
41
6
2
110
28
9
0
2
75
44
22
S
3
74
36
31
S
3
133
7
1
3
S
20
72
38
14
1
4
29
65
32
17
1
5
35
46
35
20
11
2
(22)
(46)
(28)
(4)
(75)
(19)
(6)
(0)
(51)
(30)
(15)
(3)
(51)
(25)
(21)
(3)
(92)
(5)
(1)
(2)
(14)
(50)
(26)
(10)
(1)
(20)
(45)
(22)
(12)
(1)
(24)
(31)
(24)
(14)
(7)
72
210
157
15
4
313
116
22
0
7
240
119
78
14
7
220
134
79
15
10
407
20
9
5
17
53
223
136
31
4
11
84
196
116
42
4
16
84
145
108
80
29
12
(16)
(46)
(35)
(3)
(69)
(26)
(5)
(0)
(53)
(26)
(17)
(3)
(49)
(30)
(18)
(3)
(92)
(5)
(2)
(1)
(12)
(50)
(30)
(7)
(1)
(19)
(44)
(26)
(10)
(1)
(19)
(33)
(24)
(18)
(7)
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variation between the 21 centres in providing patient diary
card data. All centres provided some data but three provided
only 25% or less. At the other end of the range, the three
most compliant centres provided 77, 78 and 91% of data.
Compliance in the provision of patient diary card data
(Table IV) was higher (52%) during the first 9 weeks, the
period of the first three courses ofchemotherapy, than subse-
quently (43%). It was unaffected by the age of patients; male
patients provided 49% of their expected data and female
42%. Patients with limited disease on admission provided less
of their data (43%) than those with extensive disease (53%).
That this was due to the change in supervision associated
with receiving radiotherapy after three courses of
chemotherapy in patients with limited disease is suggested by
the observation that the least compliant group with respect
to extent of disease were patients with limited disease during
weeks 10 to 21 when they provided 38% of data.
Performance status had a major effect on compliance
which ranged from 56% in patients with a good status (grade
0) on admission down to only 19% in those with a poor
status (grade 4). Somewhat unexpectedly, compliance was
worse (41%) with the three-course regimen than with the two
six-course regimens (51%, 49%). The reason for this may in
part be that patients in the ECMV3 group were discharged
from specialist care earlier than those in the ECMV6 and E16
groups: the least compliant patients with respect to regimen
were the ECMV3 patients during weeks 10 to 21, after the
end of their three courses of chemotherapy, when they pro-
vided 36% of data.
Table HI Compliance by centres and patients in providing quality of
life dataa
Datafrom
clinicians' reports Patient diary card data
Percentage Centres Patients Centres
ofdata provided No. (%) No. (%) No. (%)
None 1 (5) 128 (31) 0 (0)
1-25 0 (0) 32 (8) 3 (14)
26-50 0 (0) 62 (15) 8 (38)
51-75 3 (14) 60 (15) 7 (33)
76-100 17 (81) 127 (31) 3 (14)
Overall percentage (90) (47) (47)
of data received
aBased on the409 eligiblepatientswho survived atleast4weeks from
randomisation.
TableIV Percentageofdiarycarddataprovidedaccording topatients'
characteristics on admission
Number Percentage ofdataprovided
of during weeks
Characteristic patients 0-9 10-21 0-21
Age
-44 17 50 43 46
45-54 64 51 42 46
55-64 189 55 45 49
65-75 139 48 40 44
Sex
Male 270 54 45 49
Female 139 47 38 42
Extent ofdisease
Limited 241 49 38 43
Extensive 168 56 50 53
Performance status
0 83 62 52 56
1 188 55 44 49
2 93 45 40 42
3 30 44 31 37
4 2 30 2 19
Not known 13 6 4 5
Regimen
ECMV3 144 47 36 41
ECMV6 133 56 47 51
E16 132 52 45 49
All patients 409 52 43 47
Adverse reactions to treatment
The main adverse reactions, other than alopecia, that were
reported by the clinicans as being moderate or severe during
chemotherapy are shown in Table V. The findings were, in
general, very similar in the three treatment groups: 59% of
the ECMV3, 67% of the ECMV6, and 63% of the E16
patients having one or more moderate or severe reactions.
The commonest were anorexia, myelosuppression (mainly
anaemia and leucopenia), dysphagia, and vomiting. Anorexia
was reported in a higher proportion of patients in the
ECMV6 group (36%) than in the other two groups (ECMV3
29%, EI6 24%). However, unlike the other symptoms of
adverse reactions, anorexia was reported in substantial pro-
portions of patients pretreatment (Table II). When patients
with moderate or severe anorexia pretreatment are excluded,
the proportions of patients with this symptom reported as an
adverse reaction to treatment were similar in the three
groups, namely, 22% of the ECMV3, 23% of the ECMV6,
and 20% of the E16 patients.
Clinicians' assessments ofpalliation ofsymptoms
Palliation of the main symptoms (Table VI) was achieved in
high proportions of patients, ranging in the ECMV3 group
from 63% for dysphagia to 89% for haemoptysis, in the
ECMV6 group from 74% for cough to 91% for haemoptysis,
and in the E16 group from 73% for dysphagia to 86% for
haemoptysis. In the majority ofpatients palliation of a symp-
tom involved disappearance of that symptom. The propor-
tions of patients in whom palliation was achieved and in
whom symptoms disappeared were similar in the three treat-
ment groups.
The median number of days in palliation (right-hand part
of Table VI) ranged in the ECMV3 group from 94 for cough
to 164 for haemoptysis, in the ECMV6 group from 109 for
dysphagia to 162 for haemoptysis, and in the EI6 group from
126 for cough to 189 for haemoptysis. For all five of the
symptoms the median duration of palliation was 63% or
more of survival during the first year. The findings in the
three treatment groups were very similar.
Clinicians' assessments ofoverall condition, level ofphysical
activity, and breathlessness
The grades ofoverall condition, physical activity, and breath-
lessness as assessed by the clinicians are defined in Table I.
Among patients with grade 1 or worse on admission (Table
Table V Main adverse reactions other than alopecia reported by the
clinicians to be moderate or severe; based on the 443 patients who
started their allocated treatment
ECMV3 ECMV6 E16
Reaction No. (%) No. (%) No. (%)
Anorexia 44 (29) 54 (36) 34 (24)
Nausea (without vomiting) 15 (10) 17 (11) 13 (9)
Vomiting 20 (13) 25 (17) 14 (10)
Dysphagia 14 (9) 25 (17) 23 (16)
Sore mouth 22 (14) 26 (17) 11 (8)
Diarrhoea 12 (8) 9 (6) 9 (6)
Cystitis 3 (2) 5 (3) 3 (2)
Paraesthesia 13 (9) 15 (10) 8 (6)
Haematological (WHO
grade 2 or worse)
anaemia
(Hb S 9.4 gdl-) 20 (13) 32 (21) 27 (19)
leucopenia
(WBC < 2.9 x 103mm-3) 15 (10) 31 (21) 24 (17)
thrombocytopenia
(platelets
< 74 x 103mm-3) 5 (3) 8 (5) 1 (1)
Total patients with any
of the above reactions 89 (59) 100 (67) 90 (63)
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VII), the proportions who improved tended to be higher in
the E16 group although the differences were small. Thus, for
overall condition, the proportions with improvement were
49% in the ECMV3 group and 40% in the ECMV6 group
compared with 55% in the EI6 group. The corresponding
figures for level of physical activity were 43%, 48%, and
59% and for degree of breathlessness, 58%, 56% and 71%.
There was no evidence of any consistent difference between
the treatment groups in the duration of improvement.
Clinicians' assessments ofanxiety and depression
The proportions of patients with anxiety and with depression
on admission and at the three subsequent assessments are
shown in Table VIII. To avoid possible distortion of the
results by early attrition, this analysis is limited to the
patients with all the relevant data available. On admission,
17% of the ECMV3, 16% of the ECMV6 and 9% of the E16
patients were reported by their clinicians to be moderately
anxious (grade 2), and a further 8%, 3% and 4%, respec-
tively, severely so (grade 3). However, at the following three
assessments these levels of anxiety had fallen substantially.
The proportions of patients reported to be moderately or
severely depressed were lower and remained so during this
period. There was no evidence of a consistent difference
between the treatment groups with respect to either anxiety
or depression. Both anxiety and depression were somewhat
commoner and more severe in females than in males pretreat-
ment, but the proportions with improvement were similar
(details not shown).
Table VI Palliation of main symptoms as assessed by clinicians
Patients with palliation
No. of Patients Patients in Time (days) Proportion ofsurvival
Patients with whom symptom in in palliation
with symptom palliation disappeared palliation in thefirst year
Symptom Regimen pretreatment No. (%) No. (%) Median Qa Median % Qa
Cough ECMV3 140 112 (80) 91 (65) 94 51-198 (66) 43-90
ECMV6 127 94 (74) 83 (65) 131 66-198 (72) 39-92
E16 115 95 (83) 87 (76) 126 69-196 (63) 44-84
Haemoptysis ECMV3 57 51 (89) 51 (89) 164 74-221 (90) 79-94
ECMV6 44 40 (91) 39 (89) 162 74-226 (89) 64-95
E16 37 32 (86) 32 (86) 189 140-234 (92) 81-96
Chest pain ECMV3 77 66 (86) 64 (83) 115 59-185 (75) 51-87
ECMV6 63 54 (87) 51 (82) 125 68-197 (78) 50-91
E16 71 58 (82) 54 (76) 169 94-225 (82) 58-94
Anorexia ECMV3 81 63 (78) 58 (72) 129 64-189 (70) 50-83
ECMV6 75 57 (76) 54 (72) 120 79-168 (70) 50-85
E16 72 57 (79) 54 (75) 175 70-220 (77) 50-91
Dysphagia ECMV3 8 5 (63) 5 (63) 141 37-233 (88) 67-90
ECMV6 15 12 (80) 11 (73) 109 66-191 (71) 52-83
E16 11 8 (73) 8 (73) 149 10-218 (86) 50-94
IQ = interquartile range.
Table VII Overall condition, performance status, and degree of breathlessness as assessed by clinicians
Patients Patients with improvement
with grade Time (days) Proportion ofsurvival
1 or worse improved time improved
Assessment Regimen on admission No. (%) Median Qa Median % Qa
Overall ECMV3 139 68 (49) 89 42- 147 (52) 25-72
condition ECMV6 129 52 (40) 79 40-121 (41) 22-62
EC6 125 69 (55) 81 42- 159 (51) 18-76
Performance ECMV3 125 54 (43) 98 59-160 (52) 30-76
status (WHO) ECMV6 117 56 (48) 80 28-142 (48) 19-74
E16 115 68 (59) 107 53- 173 (50) 30-81
Degree of ECMV3 125 72 (58) 113 48-188 (68) 37-87
breathlessness ECMV6 124 69 (56) 84 56-157 (50) 31-80
E16 112 79 (71) 107 53-163 (50) 32-76
aQ = interquartile range.
Table VIII Clinicians' assessments ofanxietey and depression: percentages ofpatients in each grade; based on patients with
data available at all four assessments
Assessment
Number Pretreatment
of Grade Follow-up I Follow-up 2 Follow-up 3
patients 0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3
Anxiety
ECMV3 96 36 39 17 8 56 33 8 2 58 31 10 0 54 39 7 0
ECMV6 87 45 36 16 3 59 30 9 2 68 26 6 0 60 30 9 1
E16 96 56 30 9 4 59 31 8 1 57 32 8 2 68 25 7 0
Depression
ECMV3 96 66 23 10 1 70 22 7 1 70 23 6 1 69 22 8 1
ECMV6 85 67 32 1 0 69 26 4 1 76 20 4 0 64 33 2 1
EI6 96 76 18 5 1 69 23 8 0 71 24 4 1 75 17 8 01162 MRC LUNG CANCER WORKING PARTY
Patients' assessments using the diary cards
The quality of life during the first 9 weeks from the date of
randomisation (the period of the first three courses of
chemotherapy), as recorded by patients on their diary cards,
is expressed in Table IX as percentages of patient-days for
Table IX Patients' assessment ofquality oflifeduring thefirst9weeks
from the date of randomisation; based on all available data
Percentage ofpatient-days
Category recorded on diary carda
Assessment Regimen 0 1 2 3 4
Nausea ECMV3 78 15 5 2 -
ECMV6 79 15 4 2 -
E16 76 17 6 2 -
Vomiting ECMV3 90 5 3 2 -
ECMV6 92 4 3 2 -
E16 90 5 3 3 -
Dysphagia ECMV3 86 8 4 2 0
ECMV6 85 11 2 2 0
E16 93 4 2 0 0
Activity ECMV3 15 14 42 25 4
ECMV6 16 13 40 28 3
E16 17 13 39 26 4
Mood ECMV3 7 30 50 11 2
ECMV6 7 30 52 11 1
E16 10 36 45 9 1
Overall ECMV3 11 32 46 10 2
condition ECMV6 9 34 46 10 1
E16 15 43 34 8 1
aThe categories are listed in Table I.
100
100 -
80 -
60 -
40 -
20 -
0
Nausea
Dysphagia
---'.. "I
I1 -.-
each category. The results for the three treatment groups
were very similar for nausea, vomiting, and activity. There
was some indication that the results for dysphagia and for
mood were a little better for the E16 regimen than for the
ECMV regimens but the differences were small. The results
for overall condition were better for the EI6 regimen, the
percentages for the two better categories (0 and 1) combined
being 59% compared with 43% for the two ECMV regimens.
The diary card data are displayed graphically day by day
in Figures 1, 2 and 3.
Figure 1 presents the same data as are shown in Table IX,
namely data for all patients during the first three courses of
chemotherapy. For all six variables the relationship to the
three courses of chemotherapy is clear, a deterioration being
seen during the days on which chemotherapy was given,
although this was less marked for mood than for the others.
The patterns for nausea, vomiting, activity, and mood were
very similar in the three treatment groups. There was some-
what more dysphagia in the two ECMV groups than in the
EI6 group. Nausea tended to persist for longer than vomiting
between courses ofchemotherapy. Overall condition was sub-
stantially better for the E16 group between courses of
chemotherapy, suggesting that patients in this group
recovered more rapidly from the adverse effects of each
course.
Figures 2 and 3 display the data over the whole treatment
period in the subgroups of patients with limited disease
(Figure 2) and extensive disease (Figure 3) on admission. The
effects of stopping chemotherapy after three courses in the
ECMV3 group are evident, the overall levels of all six
variables remaining essentially steady after the third course in
this group compared with the other two. A comparison of
the two figures indicates a considerable, but short-lived, in-
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Figure 2 As for Figure 1. Data from patients with limited disease on admission during the whole treatment period ('rt start' and
'rt end' indicate the period of thoracic radiotherapy).
crease in dysphagia during thoracic radiotherapy in patients
with limited disease. Both figures show that with the fourth,
fifth, and sixth courses of chemotherapy, recovery after the
course was more rapid in the EI6 than the ECMV6 group,
reinforcing the conclusion from Figure 1.
All these figures show high proportions of patients in all
three groups with a low level of activity for the first day. This
is in marked contrast to the clinicians' assessments pretreat-
ment (Table II). This discrepancy almost certainly arose
because patients reported their activity level at the end of the
first day of intravenous chemotherapy while clinicians made
their assessment before it was started.
Discussion
This trial emphasises both the importance and the feasibility
of studying toxicity, the palliation of symptoms and other
aspects of quality of life in randomised comparisons between
treatment regimens in the management of lung cancer. It is
particularly important to study these endpoints in patients
with poor prognosis. Despite the inherent problems of attri-
tion and of obtaining data in this group of patients, provided
there are no treatment-related imbalances in the data, valid
comparisons can be made between treatment groups. Com-
parisons of such endpoints need to be made in randomised
trials because they may have an important bearing on treat-
ment policies, and results can be counter-intuitive (Slevin,
1992). For example, in a randomised trial in which all
patients received the same palliative drug combination for
small-cell lung cancer, the regimen was allocated at random
to be given either at conventional 3-week intervals or only as
required to control progressive disease and relieve symptoms
(Earl et al., 1991). It was expected that patients in the latter
group might require less total chemotherapy and therefore
enjoy better quality of life. In the event, less chemotherapy
was indeed given to this group but palliation of symptoms
was substantially less effective and quality of life was worse.
Quality of life analyses can be compromised by poor com-
pliance in providing data. For example, Ganz et al. (1988)
reported such a low level of compliance by patients in com-
pleting the Functional Living Index - Cancer (FLIC) ques-
tionnaire at 4-weekly intervals that they were unable to use
FLIC data in their comparison of regimen.
In the present trial, clinicians recorded their assessments of
the presence and severity (mild, moderate or severe) of
patients' symptoms and of physical activity, mood, and
overall condition at clinic attendances for chemotherapy and
follow-up. Their level of compliance in recording these
assessments was high, 90% of the expected data being pro-
vided.
With all three regimens - etoposide, cyclophosphamide,
methotrexate, and vincristine for three courses (ECMV3) or
six courses (ECMV6), or etoposide and ifosfamide for six
courses (EI6) - about two thirds of the patients were
reported by their clinicians to have experienced moderate or
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Figure 3 As for Figure 1. Data from patients with extensive disease on admission during the whole treatment period.
severe adverse effects of treatment, the commonest of which
were anorexia, myelosuppression, dysphagia, and vomiting.
The proportions of patients with reactions were very similar
in the three treatment groups, but patients in the 6-course
groups were potentially exposed to reactions on twice as
many occasions as those in the 3-course group. In this
respect, there was therefore an advantage to the 3-course
regimen.
As reported by the clinicians, all three regimens were
highly effective in palliating the symptoms of the disease.
Cough, haemoptysis, chest pain, anorexia, and dysphagia
were each palliated in 63% or more of the affected patients,
the symptom disappearing at least for a time in 57% or
more. Moreover, the median duration of palliation was 63%
or more of survival for all the above-mentioned symptoms.
The proportions of patients with improved overall condition,
level of physical activity, and breathlessness were somewhat
higher in the EI6 group than in the two ECMV groups, but
the differences were small.
The clinicians' assessments of anxiety and depression con-
sisted of recording whether each was absent, mild, moderate,
or severe. In all three treatment groups, about a third of the
patients were reported as having mild anxiety on admission,
14% moderate anxiety, and 5% severe anxiety, but these
proportions were substantially reduced over the next three
clinic attendances, suggesting that anxiety is considerably
alleviated by palliative treatment. Some 24% ofpatients were
reported to be mildly depressed on admission and 5%
moderately depressed, but less than 1% severely depressed.
In contrast to the findings for anxiety, these proportions
remained similar at subsequent assessments. They should
alert clinicians to the possibility that a small proportion of
patients might benefit from a more detailed psychological
assessment with a view to considering specific antidepressant
treatment. As reported by clinicians in the present trial, both
anxiety and depression were somewhat commoner and more
severe in female patients, but the proportions with improve-
ment were similar. The method of assessing anxiety and
depression was a relatively insensitive one. In current trials,
therefore, the MRC Lung Cancer Working Party are using
the HAD (Hospital Anxiety and Depression) scale which has
been shown to be reliable and valid (Zigmond & Snaith,
1983). We are also monitoring the use of psychotropic drugs.
Use of HAD scale data will also enable us to make better
comparisons between female and male patients.
An important feature of the trial was the use of the daily
diary card (Fayers et al., 1991). This assessment by the
patients of nausea, vomiting, difficulty in swallowing,
physical activity, mood, and overall condition was completed
every evening after their last meal for the first 21 weeks in
the trial. It has been shown to be reliable and to be sensitive
to day-to-day changes in major symptoms (Fayers et al.,
1991; MRC Lung Cancer Working Party, 1991; 1992).
Nevertheless, only 47% of the requested data was provided.
The factor that most influenced compliance was performance
status on admission, patients with a better status complying
better. There was substantial variation in compliance between
centres. This suggests that hospital and clinic staff could have
an important influence on improving compliance. The trial
protocol emphasised the need to explain to patients the
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importance of completing their cards in arriving at a
thorough assessment of their illness and its treatment. No
formal attempt was made to check on this, but informal
discussions with centres suggested that compliance is best
when clinicians or nurses encourage patients to complete
their cards and then discuss with them what they have
recorded.
Other trials have also reported difficulty in collecting
quality of life data from patients with a poor performance
status and progressing disease (Ganz et al., 1988; 1989; Ged-
des et al., 1990; MRC Lung Cancer Working Party, 1992). It
seems likely that this will remain a limitation of methods
dependent on collecting data direct from very ill patients
themselves. Patients allocated to the six-course regimens
complied somewhat better then those assigned to the three-
course regimen. This was an unexpected finding and prob-
ably occurred because patients in the three-course group were
likely to have been discharged to non-specialist care sooner
than those in the six-course groups. This emphasises the need
to explain to patients the value of daily assessments and to
encourage them to complete them.
The trial exemplifies the sensitivity of the daily diary card
in detecting day-to-day variation. The findings for the three
regimens were very similar for nausea, vomiting, and level of
physical activity. Recovery from vomiting was rapid after a
course of chemotherapy in all three groups, confirming
previous findings during chemotherapy with the ECMV
regimen (Fayers et al., 1991), but nausea and reduced
physical activity tended to persist for longer. It will therefore
be important to see whether they limit the use of
chemotherapy schedules in which drugs are given in reduced
dosage once a week (for example Miles et al., 1991), or in
which dose intensity is increased by giving the drugs in full
dosage once every 2 weeks together with haemopoietic
growth factor, a policy which the MRC Lung Cancer Work-
ing Party is currently studying.
The E16 regimen caused somewhat less dysphagia than the
ECMV regimens, and between courses of chemotherapy
patients reported themselves to be in better overall condition.
Nevertheless, these advantages need to be weighed against
the inconvenience of the 24 h infusions required, compared
with the 30 min infusions of the ECMV regimens.
Clearly it is important to find and develop the use of
quality of life instruments that are acceptable, relevant and
applicable. Apart from the daily diary card, no patient ques-
tionnaires were used in the present trial, but in its current
trials the MRC Lung Cancer Working Party are using the
Rotterdam Symptom Checklist (de Haes et al., 1990) and the
HAD scale with high levels of compliance by patients.
One limitation of the design of the present trial is that it
did not permit a reliable comparison to be made between
clinicians' and patients' assessments of quality of life because
assessments were made daily by patients but intermittently by
clinicians; also, the questions asked of each were not the
same. Nevertheless, this is an important methodological issue
(Slevin et al., 1988) and is being addressed in current MRC
Lung Cancer Working Party trials in which some of the
questions on the Rotterdam Symptom Checklist are dupli-
cated on the reports completed by clinicians.
In conclusion, although not easy, it is important to study
palliative and other quality of life endpoints in trials of
chemotherapy in the treatment of small-cell lung cancer. This
is especially necessary when, as in the present trial, a prin-
cipal aim is to improve the quality of survival. The findings
presented in this paper and in Paper 1 show that there was
no major clinical gain from continuing chemotherapy beyond
three courses or from using the ifosfamide regimen. Never-
theless, they do not exclude the possibility of a minor sur-
vival advantage with the six-course regimens (Paper 1). Even
small chances of longer survival may be important to patients
but the six-course regimens involve some 5 or 6 months of
treatment in a patient population with a median survival of
only about 9 months. Some patients might therefore prefer a
shorter treatment period. All three regimens produced high
and similar levels of palliation of the main chest symptoms,
but there was a suggestion of a minor advantage to the E16
regimen with respect to overall condition, physical activity,
breathlessness and dysphagia.
The MRC Lung Cancer Working Party are currently
studying palliative regimens of intravenous etoposide and
vincristine and of orally administered etoposide alone with
the aim of achieving high levels of palliation and low levels
of toxicity in a large programme of trials of palliative
treatments for lung cancer.
The following consultants and their colleagues entered 20 or more
patients into the trial: Brighton: J.P.R. Hartley, N.J. Hodson, C.W.
Turton; Bristol: V.L. Barley, J.A. Bullimore, R.J. White; Cambridge:
N.M. Bleehen, M.V. Williams; Cork: C.P. Bredin; Kettering: A.R.
Davidson, T.J. Williams; Leeds: D.V. Ash, H.J. Close, C.A. Joslin,
M.F. Muers, J. Stone; Mount Vernon: R.F. Ashford, S. Dische, E.P.
Dunphy, D.C. Fermont, E. Grosch, E.J. Maher, M.I. Saunders;
Oxford: R.J. Adam, C.J. Alcock, M.K. Benson, J.M. Hopkin, D.J.
Lane; York: A.M. Hunter.
The remaining patients were entered by the following consultants
and their colleagues: Carluke: J.C.J.L. Bath; Chesterfield: J.W.
Hadfield; Inverness: W.D. Murray; Ipswich: C.R. Wiltshire; Midd-
lesex; R. Berry, A.M. Jelliffe, A.R. Makepeace, M.F. Spittle; Milton
Keynes: S. Fisher; Northampton: G.C. Ferguson; Plymouth: J.M.
Brindle, A.F. Broad, C.R. McGavin; Sheffield: J.J. Bolger, A.E.
Champion, K. Dunn, I.H. Manifold; Stoke Mandeville: S.J. Wil-
liams; Swindon: J.A. Waddell; Wolverhampton: D.J. Fairlamb.
The reference histopathologist was P.G.I. Stovin.
Local coordinators were: A. Anderson, R. Collins, L. Crossley,
C. des Rochers, A. Fenwick, S. Garner, L. Grant, C. Hutchinson,
V. Marmur, A. Pickett, D. Robinson, C. Schuerman, K. Weiner and
T. Young.
The MRC Trials Office data managers were: Elizabeth Brodnicki,
Grazyna Lallemand and Sheila Thornton.
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